We would like to thank Armoiry et al1 for investing the time and effort to further advance our research.We carefully considered their solution to our assumption regarding the equal relative effectiveness of bortezomib (Bor) versus dexamethasone (Dex) and bortezomib plus dexamethasone (BorDex) versus Dex. [...]

Supported by Grant No. 152001020 from ZonMw, the Netherlands Organisation for Health Research and Development.
doi.org/10.1200/JCO.2017.73.7569, hdl.handle.net/1765/101935
Journal of Clinical Oncology

van Beurden-Tan, C., Franken, M., Blommestein, H., Uyl-de Groot, C., & Sonneveld, P. (2017). Reply to X. Armoiry et al. Journal of Clinical Oncology, 35(25), 2976–2977. doi:10.1200/JCO.2017.73.7569